"10.1371_journal.pone.0050498","plos one","2012-11-29T00:00:00Z","Noah J Tubo; Marc A Wurbel; Trevor T Charvat; Thomas J Schall; Matthew J Walters; James J Campbell","Brigham and Women’s Hospital, Department of Dermatology, Boston, Massachusetts, United States of America; Harvard Medical School, Program in Biological and Biomedical Sciences, Boston, Massachusetts, United States of America; ChemoCentryx, Inc., 850 Maude Avenue, Mountain View, California, United States of America; Harvard Medical School, Departments of Dermatology and Pathology, Boston, Massachusetts, United States of America","Conceived and designed the experiments: JJC MJW. Performed the experiments: NJT MAW JJC. Analyzed the data: NJT JJC. Contributed reagents/materials/analysis tools: TTC TJS. Wrote the paper: JJC NJT.","The authors have read the journal’s policy and have the following conflicts. TTC, TJS and MJS are employees of Chemocentryx, Inc, which owns rights to CCX8037. Trevor T. Charvat, Cheng Hu, Anita Melikian, Aaron Novack, Andrew M.K. Pennell, Jay Powers, Sreenivas Punna, Edward J. Sullivan, William D.Thomas, Solomon Ungashe, Penglie Zhang. N-(2-(Hetaryl)Aryl)Arylsulfonamides and N-(2-(Hetaryl)Hetaryl) Arylsufonamides. PCT patent application WO2009038847 3/26/2009. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2012","11","Noah J Tubo","NJT",6,TRUE,2,3,2,2,TRUE,TRUE,FALSE,0,NA,FALSE
